Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist

التفاصيل البيبلوغرافية
العنوان: Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist
المؤلفون: H M, Sarau, D E, Griswold, B, Bush, W, Potts, P, Sandhu, D, Lundberg, J J, Foley, D B, Schmidt, E F, Webb, L D, Martin, J J, Legos, R G, Whitmore, F C, Barone, A D, Medhurst, M A, Luttmann, G A, Giardina, D W, Hay
المصدر: The Journal of pharmacology and experimental therapeutics. 295(1)
سنة النشر: 2000
مصطلحات موضوعية: Male, Mice, Inbred BALB C, Dose-Response Relationship, Drug, Brain, Iris, Receptors, Neurokinin-3, CHO Cells, In Vitro Techniques, Substance P, Peptide Fragments, Rats, Rats, Sprague-Dawley, Mice, Cricetinae, Quinolines, Animals, Humans, Calcium, Rabbits
الوصف: The pharmacological and pharmacokinetic profile of SB-222200 [(S)-(-)-N-(alpha-ethylbenzyl)-3-methyl-2-phenylquinoline-4-car boxami de], a human NK-3 receptor (hNK-3R) antagonist, was determined. SB-222200 inhibited (125)I-[MePhe(7)]neurokinin B (NKB) binding to Chinese hamster ovary (CHO) cell membranes stably expressing the hNK-3 receptor (CHO-hNK-3R) with a K(i) = 4.4 nM and antagonized NKB-induced Ca(2+) mobilization in HEK 293 cells stably expressing the hNK-3 receptor (HEK 293-hNK-3R) with an IC(50) = 18.4 nM. SB-222200 was selective for hNK-3 receptors compared with hNK-1 (K(i)100,000 nM) and hNK-2 receptors (K(i) = 250 nM). In HEK 293 cells transiently expressing murine NK-3 receptors (HEK 293-mNK-3R), SB-222200 inhibited binding of (125)I-[MePhe(7)]NKB (K(i) = 174 nM) and antagonized NKB (1 nM)-induced calcium mobilization (IC(50) = 265 nM). In mice oral administration of SB-222200 produced dose-dependent inhibition of behavioral responses induced by i.p. or intracerebral ventricular administration of the NK-3 receptor-selective agonist, senktide, with ED(50) values of approximately 5 mg/kg. SB-222200 effectively crossed the blood-brain barrier in the mouse and rat. The inhibitory effect of SB-222200 against senktide-induced behavioral responses in the mouse correlated significantly with brain, but not plasma, concentrations of the compound. Pharmacokinetic evaluation of SB-222200 in rat after oral administration (8 mg/kg) indicated sustained plasma concentrations (C(max) = about 400 ng/ml) and bioavailability of 46%. The preclinical profile of SB-222200, demonstrating high affinity, selectivity, reversibility, oral activity, and central nervous system penetration, suggests that it will be a useful tool compound to define the physiological and pathophysiological roles of NK-3 receptors, in particular in the central nervous system.
تدمد: 0022-3565
URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid________::cd478ee8b89d7e1dead7891aa99f62eb
https://pubmed.ncbi.nlm.nih.gov/10992004
رقم الأكسشن: edsair.pmid..........cd478ee8b89d7e1dead7891aa99f62eb
قاعدة البيانات: OpenAIRE